Navigation Links
Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
Date:7/15/2009

BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID). The analysis finds that bleeding associated with edoxaban is most closely correlated with minimum concentration levels of the drug in the blood, and that these trough levels may best predict bleeding events, rather than total exposure or maximum concentration levels.

These findings were presented today at the XXII International Society on Thrombosis and Haemostasis Congress in Boston. Edoxaban is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568) as a potential treatment for the prevention of both arterial and venous thromboembolism; a Phase III trial is underway among patients with AF.

This pharmacokinetic (PK) analysis of the Phase IIb study examined the relationship between bleeding events reported in patients taking 30 or 60 mg edoxaban given either QD or BID and the concentration of edoxaban in their blood. The analysis examined overall bleeding rates when drug concentration levels reached the highest points (known as Cmax), lowest points (known as Cmin) as well as overall edoxaban exposure (measured by area under the curve or AUC). Delivering a compound twice per day generally allows for more consistent concentration levels in the blood. With twice-daily dosing, the Cmin levels (troughs) do not dip as low, and the Cmax levels (peaks) do not reach as high as when the compound is delivered once per day.

"When we assessed the pharmacokinetics in patients taking edoxaban once a day, lower minimum concentrations and fewer bleeding events were observed, compared to the same total daily dosage give
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...C,Md.,Nov.24/PRNewswire/--Inadditiontofamily,frien...ladelphiajurorstoherThanksgivinggratitudelist. ,...nkfultothem,"shesaidofMonday,sverdictstotaling$103... Wisneskiisamong12,000womennationwidewhohavesuedWy...apydrugsPremarinandPrempro.Wisneskiandtheothervict...
(Date:11/24/2009)...GO,Nov.24/PRNewswire/--Accumetrics,Inc.,aprivately...m,thefirstrapidandeasy-to-usediagnosticsystemforme...tagents(e.g.Plavix®andaspirin),announcedtoday...dGregoryJ.Tibbitts,ChiefFinancialOfficerofAccumetr...ualPiperJaffrayHealthCareConferencebeingheldinNewY...
(Date:11/24/2009)...H,N.C.,Nov.24/PRNewswire/--PharmaceuticalInstitute...thepharmaceuticalandbiotechindustry,todayannounced... .Thenew HospitalMarketplace e-courseisthenewestad...series,acomprehensiveseriesofe-coursesdesignedtofi...knowledgeforcommercialprofessionals. ,, Thenewt...
Breaking Medicine Technology:Maryland Woman Thankful for Wyeth Verdicts 2Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2Pitt researchers net 245 million from NIH to explore better ways to grow cells 10117 1Pitt researchers net 245 million from NIH to explore better ways to grow cells 10117 2Pitt researchers net 245 million from NIH to explore better ways to grow cells 10117 3NIH fellowship recipient to study disease ecology 10115 1NIH fellowship recipient to study disease ecology 10115 2MSU licenses plant oil enhancement technology to BASF Plant Science 10113 1MSU licenses plant oil enhancement technology to BASF Plant Science 10113 2
(Date:11/25/2009)...vors often plagued by neurological symptoms, study...y News) -- Neurological side effects are among the...f testicular cancer who were treated with cisplati...The study included 1,409 Norwegian men treated for...4 who took part in a follow-up survey conducted fr...
(Date:11/25/2009)..., ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--Th...entHealthCareFraudActof2009,"S.2128,whichisdesigne...opreventfraudinMedicare.ThebillwasintroducedbySen....sseveralprovisionstheAmericanAssociationforHomecar...eAssociationproposedtoCongressinFebruary.Thoseprov...
(Date:11/25/2009)...rug used to treat colorectal cancer also can rever...d first-line therapy for the disease, researchers ...s week. , Mntrier,s disease causes thickening of ...and vomiting, as well as anemia and swelling in th...e at increased risk for gastric cancer. Previously...
(Date:11/25/2009)... found puffs of air on flesh that mimicked parts o..., WEDNESDAY, Nov. 25 (HealthDay News) -- People ca...heir skin, new research shows. , In fact, sensa...of speech actually helped people decipher sounds b...e never been able to show whether we could use tac...
(Date:11/25/2009)... BioSpace.com, the premier res...veiled the third edition of the BioForest™ H... Englewood, CO (Vocus) November 25, 2009 -- B... careers and information, unveiled the third editi...rning., , , , ,This regional campaign is a promot...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
... The North Bengal Medical College and Hospital has... of HIV-positive persons as baseless. // The...a, said here today that the allegation had no basi... NBMCH and alleged that the HIV patients were not ...
... Ranbaxy Laboratories Ltd has received approval fr...ne Tablets in the US market.// The company i...approval for marketing the antibiotic in strengths...tory tract and urinary tract infections, skin and ...
... ‘YUVA’ is Youth Unite for Victory against AIDS, a...ess among 450 million youth and adolescents in the...rgency in implementing the action plan by the mini...DS could particularly be a youth problem. So he ex...
... The condition of Rahul Mahajan, son of late BJP l...r he was admitted to a private hopital here in the...tra was brought in dead. 'Rahul's condition i...se of Mahajan's ailment, Thakur said it was being ...
... Max Healthcare Thursday opened its sixth hospital...es under one roof//. Together with the new 20...pital complex of Max will now offer 450 bed facili...t Saket will offer all super-speciality care. We m...
... History repeats itself, this is made evident yet ...cond time. This is a notifiable fish disease in a ...ent Fisheries and Aquaculture Science (Cefas) has ...virus is thought to be a very serious hazard to fi...
Other Medicine News:Health News:Saket Hospital to get Multi-speciality Facilities from Max Healthcare 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: